HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Scimitar Syndrome

An anomalous pulmonary venous return in which the right PULMONARY VEIN is not connected to the LEFT ATRIUM but to the INFERIOR VENA CAVA. Scimitar syndrome is named for the crescent- or Turkish sword-like shadow in the chest radiography and is often associated with hypoplasia of the right lung and right pulmonary artery, and dextroposition of the heart.
Also Known As:
Anomalous Pulmonary Venous Return; Pulmonary Venous Return Anomaly; Scimitar Anomaly; TAPVR; TAPVR1; Total Anomalous Pulmonary Venous Return; Total Anomalous Pulmonary Venous Return 1; Anomaly, Scimitar
Networked: 167 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pulmonary Vein Stenosis
2. Birth Weight (Birth Weights)
3. Pulmonary Hypertension
4. Scimitar Syndrome
5. Ventricular Heart Septal Defects (Ventricular Septal Defect)

Experts

1. Bichell, David P: 2 articles (12/2022 - 11/2019)
2. Andersen, Nicholas D: 2 articles (07/2021 - 10/2020)
3. Turek, Joseph W: 2 articles (07/2021 - 10/2020)
4. Lin, Angela E: 2 articles (11/2015 - 04/2011)
5. Schranz, Dietmar: 2 articles (10/2013 - 03/2002)
6. Chen, Yi-Yung: 2 articles (09/2013 - 09/2006)
7. Kirshbom, P M: 2 articles (03/2008 - 01/2008)
8. Kogon, B E: 2 articles (03/2008 - 01/2008)
9. Masterson, K: 2 articles (03/2008 - 01/2008)
10. Simsic, J M: 2 articles (03/2008 - 01/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Scimitar Syndrome:
1. GadoliniumIBA
2. esmolol (Brevibloc)FDA LinkGeneric
3. 4- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA
4. Nitric Oxide (Nitrogen Monoxide)FDA Link
5. Anesthetics (Anesthetic Agents)IBA
6. Coenzyme A (CoA)IBA
7. Warfarin (Coumadin)FDA LinkGeneric
8. Vasodilator Agents (Vasodilators)IBA
9. Epoprostenol (Prostacyclin)FDA LinkGeneric
10. Polytetrafluoroethylene (Teflon)FDA Link

Therapies and Procedures

1. Cardiopulmonary Bypass (Heart-Lung Bypass)
2. Extracorporeal Membrane Oxygenation
02/01/2020 - "In addition, recent group had more comorbidities including chromosomal anomalies, total anomalous pulmonary venous return, and kidney anomalies (5.6% vs. 3.6%, 2.3% vs. 1.7%, and 5.6% vs. 3.6%, respectively, p < 0.001); these were associated with a higher rate of extracorporeal membrane oxygenation utilization (9.2% vs. 4.5%, p < 0.001). "
10/01/2016 - "Extracorporeal Membrane Oxygenation in a 1,360-g Premature Neonate after Repairing Total Anomalous Pulmonary Venous Return."
03/01/2023 - "Multivariable analysis found extracorporeal membrane oxygenation support (hazard ratio, 10.4; 95% confidence interval, 4.3-25.4; P < .001), total anomalous pulmonary venous return (hazard ratio, 4.3; 95% confidence interval, 1.7-10.8; P = .002), and birth weight 2.5 kg or less (hazard ratio, 2.4; 95% confidence interval, 1.0-5.4; P = .041) to be independent risk factors for mortality in all-comers. "
11/01/2010 - "All infants with a diagnosis of TAPVR as an isolated lesion who underwent surgical repair at Children's Hospital of Wisconsin from 1991 to 2007 were reviewed to assess location of drainage, presence of obstruction, age at presentation, age at surgery, death, need for extracorporeal membrane oxygenation (ECMO), length of hospital stay, length of mechanical ventilation (MV), and late pulmonary venous obstruction. "
05/01/2015 - "The recipient was a 26-year-old woman with idiopathic pulmonary arterial hypertension and the graft ischemic time was prolonged significantly because of the time required to induce peripheral veno-arterial extracorporeal membrane oxygenation (V-A ECMO) under local anesthesia, and address the severe intrathoracic and pericardial adhesions from past surgery for partial anomalous pulmonary venous return, with concurrent annular plication of the tricuspid valve. "
3. Therapeutics
4. Length of Stay
5. Arterial Switch Operation